{"nctId":"NCT00137969","briefTitle":"A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus","startDateStruct":{"date":"2005-05-10","type":"ACTUAL"},"conditions":["Lupus Erythematosus, Systemic"],"count":262,"armGroups":[{"label":"Rituximab 1000 mg + prednisone","type":"EXPERIMENTAL","interventionNames":["Drug: Rituximab","Drug: Prednisone","Drug: Acetaminophen","Drug: Diphenhydramine"]},{"label":"Placebo + prednisone","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Prednisone","Drug: Acetaminophen","Drug: Diphenhydramine"]}],"interventions":[{"name":"Rituximab","otherNames":["Rituxan","MabThera","Zytux"]},{"name":"Placebo","otherNames":[]},{"name":"Prednisone","otherNames":[]},{"name":"Acetaminophen","otherNames":[]},{"name":"Diphenhydramine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of systemic lupus erythematosus (SLE).\n* Active disease at screening.\n* Stable use of one immunosuppressive drug.\n* Use of an antimalarial drug.\n* For subjects of reproductive potential (males and females), use of a reliable means of contraception throughout their study participation.\n\nExclusion Criteria:\n\n* Unstable patients with thrombocytopenia experiencing or at high risk for developing clinically significant bleeding or organ dysfunction requiring therapies such as plasmapheresis or acute blood or platelet transfusions.\n* Active moderate to severe glomerulonephritis.\n* Retinitis, poorly controlled seizure disorder, acute confusional state, myelitis, stroke or stroke syndrome, cerebellar ataxia, or dementia that is currently active and resulting from SLE.\n* Lack of peripheral venous access.\n* Pregnant women or nursing (breast feeding) mothers.\n* History of severe, allergic, or anaphylactic reactions to humanized or murine monoclonal antibodies.\n* Significant, uncontrolled medical disease in any organ system not related to SLE that in the investigator's opinion would preclude subject participation.\n* Concomitant conditions that require oral or systemic corticosteroid use.\n* Known human immunodeficiency virus (HIV) infection.\n* Known active infection of any kind (excluding fungal infection of nail beds) or any major episode of infection requiring hospitalization or treatment with intravenous (IV) antibiotics.\n* History of deep space infection.\n* History of serious recurrent or chronic infection.\n* History of cancer, including solid tumors, hematological malignancies, and carcinoma in situ.\n* Active alcohol or drug abuse, or history of alcohol or drug abuse.\n* Major surgery.\n* Previous treatment with CAMPATH-1H antibody.\n* Previous treatment with any B cell-targeted therapy.\n* Treatment with any investigational agent within 28 days of screening (Day -7) or 5 half-lives of the investigational drug (whichever is longer).\n* Receipt of a live vaccine within 28 days prior to screening.\n* Intolerance or contraindication to oral or IV corticosteroids.\n* Use of a new immunosuppressive drug prior to screening or change in dose of ongoing immunosuppressive drug prior to screening.\n* Prednisone dose of â‰¥ 1 mg/kg/day prior to screening.\n* Treatment with cyclophosphamide or a calcineurin inhibitor.\n* Treatment with a second immunosuppressive or immunomodulatory drug.\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 2.5 x the upper limit of normal.","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"75 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Who Achieved a Major Clinical Response (MCR), Partial Clinical Response (PCR), or Nonclinical Response (NCR) Defined by British Isles Lupus Assessment Group (BILAG) Scores Over The 52-week Treatment Period","description":"The BILAG Index measures clinical disease activity in Systemic Lupus Erythematosus (SLE). A single alphabetic score (A through E) is used to denote disease severity for each of the 8 domains. The global BILAG score is the sum of a converted numerical score (A=9, B=3, C=1, D=0, E=0) over 8 domains. MCR = participants who achieved BILAG C scores or better at 24 weeks, maintained this response without developing a flare to 52 weeks, and did not experience a severe flare from Day 1 to Week 24; PCR = participants who achieved BILAG C score or better at 24 wks and maintained response without a flare for 16 consecutive weeks, or maximum of one BILAG B score at 24 weeks and maintained response without a flare to 52 wks, or maximum of 2 BILAG B scores at 24 wks without development of BILAG scores of A or B until Week 52 if the baseline BILAG score was 1A+\\>=2Bs, or\\>=2 As, or\\>=4 Bs, or participants who enrolled with scores of severe disease and did not achieve a single BILAG B at Month 6.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"119","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]}]},{"type":"SECONDARY","title":"Time-adjusted Area Under The Curve Minus Baseline (AUCMB) of BILAG Score Over The 52-week Treatment Period","description":"The BILAG Index measures clinical disease activity in SLE. A single alphabetic score (A through E) is used to denote disease severity for each of the 8 domains. The global BILAG score is the sum of a converted numerical score (A=9, B=3, C=1, D=0, E=0) over 8 domains. The AUCMB of BILAG Score Over 52 Weeks was calculated as: 1. Calculate the AUC of the BILAG global score versus time (in days) by 52 weeks. 2. Calculate the Time-Adjusted AUC by dividing the AUC by the number of days a patient was on the study. 3. Minus the Time-Adjusted AUC by the baseline BILAG global score","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.8","spread":"4.0"},{"groupId":"OG001","value":"-5.9","spread":"4.5"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Achieved an MCR (Excluding PCR)","description":"The BILAG Index measures clinical disease activity in SLE. A single alphabetic score (A through E) is used to denote disease severity for each of the 8 domains. The global BILAG score is the sum of a converted numerical score (A=9, B=3, C=1, D=0, E=0) over 8 domains. MCR = participants who achieved BILAG C scores or better at 24 weeks, maintained this response without developing a flare to 52 weeks, and did not experience a severe flare from Day 1 to Week 24. PCR = participants who achieved BILAG C score or better at 24 wks and maintained response without a flare for 16 consecutive weeks, or maximum of one BILAG B score at 24 weeks and maintained response without a flare to 52 wks, or maximum of 2 BILAG B scores at 24 wks without development of BILAG scores of A or B until Week 52 if the baseline BILAG score was 1A+\\>=2Bs, or\\>=2 As, or\\>=4 Bs, or participants who enrolled with scores of severe disease and did not achieve a single BILAG B at Month 6.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Achieved a PCR (Including MCR)","description":"The BILAG Index measures clinical disease activity in SLE. A single alphabetic score (A through E) is used to denote disease severity for each of the 8 domains. The global BILAG score is the sum of a converted numerical score (A=9, B=3, C=1, D=0, E=0) over 8 domains. PCR = participants who achieved BILAG C score or better at 24 wks and maintained response without a flare for 16 consecutive weeks, or maximum of one BILAG B score at 24 weeks and maintained response without a flare to 52 wks, or maximum of 2 BILAG B scores at 24 wks without development of BILAG scores of A or B until Week 52 if the baseline BILAG score was 1A+\\>=2Bs, or\\>=2 As, or\\>=4 Bs, or participants who enrolled with scores of severe disease and did not achieve a single BILAG B at Month 6. MCR = participants who achieved BILAG C or better at 24 weeks, maintained this response without developing a flare to 52 weeks, and did not experience a severe flare from Day 1 to Week 24.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Achieved a BILAG C or Better in All Domains","description":"The BILAG Index measures clinical disease activity in SLE. A single alphabetic score (A through E) is used to denote disease severity for each of the 8 domains. The global BILAG score is the sum of a converted numerical score (A=9, B=3, C=1, D=0, E=0) over 8 domains.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Moderate or Severe Flare","description":"The BILAG Index measures clinical disease activity in SLE. A single alphabetic score (A through E) is used to denote disease severity for each of the 8 domains. The global BILAG score is the sum of a converted numerical score (A=9, B=3, C=1, D=0, E=0) over 8 domains. A severe flare = participants had BILAG A score(s) present in one or more domains or BILAG B scores present in three or more domains at the same visit following a visit of inactive disease state defined above. A moderate flare = participants had only BILAG B scores present in two domains at the same visit following a visit of inactive disease state.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"112.0","spread":null},{"groupId":"OG001","value":"126.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in SLE Expanded Health Survey Physical Function Score From Baseline","description":"Short Form (36) with additional questions specific to lupus (scale = 0-100; with 100 representing the highest level of functioning possible) to measure the ability of rituximab to improve quality of life. A positive value for this outcome measure indicates that symptoms have improved.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":"22.8"},{"groupId":"OG001","value":"4.1","spread":"17.9"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Achieved an MCR in The ITT Population","description":"The BILAG Index measures clinical disease activity in SLE. A single alphabetic score (A through E) is used to denote disease severity for each of the 8 domains. The global BILAG score is the sum of a converted numerical score (A=9, B=3, C=1, D=0, E=0) over 8 domains. MCR = participants who achieved BILAG C scores or better at 24 weeks, maintained this response without developing a flare to 52 weeks, and did not experience a severe flare from Day 1 to Week 24.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":72,"n":169},"commonTop":["Upper Respiratory Tract Infection","Urinary Tract Infection","Nausea","Headache","Arthralgia"]}}}